5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 10, 2006, Pages 2791-2795

  Kuduk, Scott D ^a   Di Marco, Christina Ng ^a   Chang, Ronald K ^a   Wood, Michael R ^a   Kim, June J ^a   Schirripa, Kathy M ^a   Murphy, Kathy L ^a   Ransom, Richard W ^a   Tang, Cuyue ^a   Torrent, Maricel ^a   Ha, Sookhee ^a   Prueksaritanont, Thomayant ^a   Pettibone, Douglas J ^a   Bock, Mark G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonists; Bioactivation; Bradykinin B1; Diaminopyridine

Indexed keywords

2,3 DIAMINOPYRIDINE; 5 PIPERAZINYLPYRIDINE CARBOXAMIDE; AMINO ACID DERIVATIVE; AMINOPYRIDINE DERIVATIVE; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; NONHUMAN; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION;

HUMANS; MODELS, MOLECULAR; PIPERAZINES; RECEPTOR, BRADYKININ B1;

ANIMALIA;

EID: 33645872981     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.01.112     Document Type: Article

References (13)

1. Couture R., Harrison M., Vianna R.M., and Cloutier F. Eur. J. Pharmacol. 429 (2001) 161
2. Regoli D., and Barabé. J. Pharmacol. Rev. 32 (1980) 1
3. Marceau F. Immunopharmacology 30 (1995) 1
4. Mason G.S., Cumberbatch M.J., Hill R.G., and Rupniak N.M.J. Can. J. Physiol. Pharmacol. 80 (2002) 264
5. Stewart J.M., Gera L., Chan D.C., Whalley E.T., Hanson W.L., and Zuzack J.S. Can. J. Physiol. Pharmacol. 75 (1997) 719
6. Bock M.G., Hess J.F., and Pettibone D.J. In: Doherty A.M. (Ed). Annual Reports in Medicinal Chemistry Vol. 38 (2003), Elsevier, USA 111
7. Pesquero J.B., Araújo R.C., Heppenstall P.A., Stucky C.L., Silva J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., Lewin G.R., and Bader M. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8140
8. Feng D.M., Wai J.M., Kuduk S.D., Ng C., Murphy K.L., Ransom R.W., Reiss D., Chang R.S.-L., Harrell C.M., Tang C., Prueksaritanont T., Freidinger R.M., Pettibone D.J., and Bock M.G. Bioorg. Med. Chem Lett. 15 (2005) 2385
9. Kuduk S.D., Ng C., Feng D.M., Wai J., Chang R.S.L., Harrell C.M., Murphy K.L., Ransom R.W., Reiss D., Prueksaritanont T., Tang C., Mason G., Boyce S., Freidinger R.M., Pettibone D.J., and Bock M.G. J. Med. Chem. 47 (2004) 6439
10. Tang C., Subramanian R., Kuo Y., Krymgold S., Liu P., Kuduk S.D., Ng C., Feng D.M., Elmore C., Soli P., Ho J., Bock M.G., Ballie T.A., and Prueksaritanont T. Chem. Res. Toxicol. 18 (2005) 934
11. Compounds 8 and 9 were accessed via borane reduction of compounds 10 and 11, respectively.
12. Su D.S., Markowitz K., DiPardo R.M., Murphy K.L., Harrell C.M., O'Malley S.S., Ransom R.W., Chang R.S.L., Ha S., Hess F.J., Pettibone D.J., Mason G., Boyce S., Freidinger R.M., and Bock M.G. J. Am. Chem. Soc. 125 (2003) 7516
13. Ha S.N., Hey P., Ransom R.W., Harrell C.M., Murphy K.L., Chang R.S.L., Chen T.B., Su D.S., Markowitz K., Bock M.G., Freidinger R.M., and Hess F.J. Biochem. Biophys. Res. Commun. 331 (2005) 159